Oligonucleotide Synthesis Comprehensive Study by Type (Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents, Others), Application (Therapeutic, Research, Diagnostic), End-User (Hospitals, Pharmaceutical & Biotechnology, Diagnostic Laboratories, Academic Research Institutes, Others) Players and Region - Global Market Outlook to 2028

Oligonucleotide Synthesis Market by XX Submarkets | Forecast Years 2023-2028  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Oligonucleotide Synthesis Market Scope
The chemical synthesis of relatively small nucleic acid fragments with a known chemical structure (sequence) is known as oligonucleotide synthesis. The method is very helpful in modern laboratory practice since it gives quick, low-cost access to oligonucleotides manufactured to order with the necessary sequence. Chemical oligonucleotide synthesis does not have this restriction, even though it is typically carried out in the opposite, 3' to 5' direction, whereas enzymes can only manufacture DNA and RNA in a 5' to 3' direction.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledAlnylam Pharmaceuticals, Inc., Biogen Inc., Danaher Corporation, Eurofins Scientific, Ionis Pharmaceuticals, Inc., Kaneka Corporation, Diagenode, LGC Limited, Merck KGAA, Sarepta Therapeutics, Inc. and Thermo Fisher Scientific, Inc.
CAGR%


The competitive landscape for the oligonucleotide synthesis industry gives information by competitor. Included information includes a business overview, financials, revenue generated, market potential, investments in R&D, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launches, product breadth and depth, and application dominance. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Oligonucleotide Synthesis market throughout the predicted period.

Alnylam Pharmaceuticals, Inc., Biogen Inc., Danaher Corporation, Eurofins Scientific, Ionis Pharmaceuticals, Inc., Kaneka Corporation, Diagenode, LGC Limited, Merck KGAA, Sarepta Therapeutics, Inc. and Thermo Fisher Scientific, Inc. are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Oligonucleotide Synthesis market by Type , by Application (Therapeutic, Research and Diagnostic) and Region with country level break-up.

On the basis of geography, the market of Oligonucleotide Synthesis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2022.

In 2021, Diagenode launched a new small RNA-sequencing solution, D-Plex Small RNA DNBSEQ Kit for MGI's DNBSEQ sequencers. The kit includes unique D-Plex technology for library construction, allowing for great performance with ultralow RNA inputs and identification of different tiny RNA transcripts.
For instance, the "Genome India Project" (GIP) launched by the Department of Biotechnology (DBT) in January 2020. To create a reference genome, the project intends to gather 10,000 genetic samples from Indian residents throughout the country. Precision health, rare genetic illnesses, the spectrum of genetic and complex diseases in the Indian population, genetic epidemiology of multifactorial lifestyle diseases, and translational research are some of the project's key focal areas. Furthermore, important players in this developing region open up a promising market for oligonucleotide synthesis

Influencing Trend:
Growing applications of synthesized oligonucleotides in molecular diagnostics & clinical applications

Market Growth Drivers:
An increase in government funding for DNAstudies, synthetic biology initiatives, and rigorous research and R&D expenditure in pharmaceutical and biotechnology companies

Restraints:
Complexities associated with therapeutic oligos and Challenging delivery of oligonucleotide drugs to specific targets

Opportunities:
Growth opportunities in emerging economies and Rise in focus on personalised medicine

Key Target Audience
Oligonucleotide Therapeutics Society, Bespoke Oligonucleotide Synthesis Service and Partnerships, Indian Medical Association, Department of Biotechnology and Others

Report Objectives / Segmentation Covered

By Type
  • Oligonucleotide-Based Drugs
  • Synthesized Oligonucleotides
  • Reagents
  • Others
By Application
  • Therapeutic
  • Research
  • Diagnostic
By End-User
  • Hospitals
  • Pharmaceutical & Biotechnology
  • Diagnostic Laboratories
  • Academic Research Institutes
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. An increase in government funding for DNAstudies, synthetic biology initiatives, and rigorous research
      • 3.2.2. R&D expenditure in pharmaceutical and biotechnology companies
    • 3.3. Market Trends
      • 3.3.1. Growing applications of synthesized oligonucleotides in molecular diagnostics & clinical applications
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Oligonucleotide Synthesis, by Type, Application, End-User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Oligonucleotide Synthesis (Value)
      • 5.2.1. Global Oligonucleotide Synthesis by: Type (Value)
        • 5.2.1.1. Oligonucleotide-Based Drugs
        • 5.2.1.2. Synthesized Oligonucleotides
        • 5.2.1.3. Reagents
        • 5.2.1.4. Others
      • 5.2.2. Global Oligonucleotide Synthesis by: Application (Value)
        • 5.2.2.1. Therapeutic
        • 5.2.2.2. Research
        • 5.2.2.3. Diagnostic
      • 5.2.3. Global Oligonucleotide Synthesis by: End-User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Pharmaceutical & Biotechnology
        • 5.2.3.3. Diagnostic Laboratories
        • 5.2.3.4. Academic Research Institutes
        • 5.2.3.5. Others
      • 5.2.4. Global Oligonucleotide Synthesis Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Oligonucleotide Synthesis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Alnylam Pharmaceuticals, Inc.
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Biogen Inc.
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Danaher Corporation
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eurofins Scientific
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Ionis Pharmaceuticals, Inc.
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Kaneka Corporation
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Diagenode
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. LGC Limited
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck KGAA
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sarepta Therapeutics, Inc.
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Thermo Fisher Scientific, Inc.
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Oligonucleotide Synthesis Sale, by Type, Application, End-User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Oligonucleotide Synthesis (Value)
      • 7.2.1. Global Oligonucleotide Synthesis by: Type (Value)
        • 7.2.1.1. Oligonucleotide-Based Drugs
        • 7.2.1.2. Synthesized Oligonucleotides
        • 7.2.1.3. Reagents
        • 7.2.1.4. Others
      • 7.2.2. Global Oligonucleotide Synthesis by: Application (Value)
        • 7.2.2.1. Therapeutic
        • 7.2.2.2. Research
        • 7.2.2.3. Diagnostic
      • 7.2.3. Global Oligonucleotide Synthesis by: End-User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Pharmaceutical & Biotechnology
        • 7.2.3.3. Diagnostic Laboratories
        • 7.2.3.4. Academic Research Institutes
        • 7.2.3.5. Others
      • 7.2.4. Global Oligonucleotide Synthesis Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Oligonucleotide Synthesis: by Type(USD Million)
  • Table 2. Oligonucleotide Synthesis Oligonucleotide-Based Drugs , by Region USD Million (2017-2022)
  • Table 3. Oligonucleotide Synthesis Synthesized Oligonucleotides , by Region USD Million (2017-2022)
  • Table 4. Oligonucleotide Synthesis Reagents , by Region USD Million (2017-2022)
  • Table 5. Oligonucleotide Synthesis Others , by Region USD Million (2017-2022)
  • Table 6. Oligonucleotide Synthesis: by Application(USD Million)
  • Table 7. Oligonucleotide Synthesis Therapeutic , by Region USD Million (2017-2022)
  • Table 8. Oligonucleotide Synthesis Research , by Region USD Million (2017-2022)
  • Table 9. Oligonucleotide Synthesis Diagnostic , by Region USD Million (2017-2022)
  • Table 10. Oligonucleotide Synthesis: by End-User(USD Million)
  • Table 11. Oligonucleotide Synthesis Hospitals , by Region USD Million (2017-2022)
  • Table 12. Oligonucleotide Synthesis Pharmaceutical & Biotechnology , by Region USD Million (2017-2022)
  • Table 13. Oligonucleotide Synthesis Diagnostic Laboratories , by Region USD Million (2017-2022)
  • Table 14. Oligonucleotide Synthesis Academic Research Institutes , by Region USD Million (2017-2022)
  • Table 15. Oligonucleotide Synthesis Others , by Region USD Million (2017-2022)
  • Table 16. South America Oligonucleotide Synthesis, by Country USD Million (2017-2022)
  • Table 17. South America Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 18. South America Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 19. South America Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 20. Brazil Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 21. Brazil Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 22. Brazil Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 23. Argentina Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 24. Argentina Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 25. Argentina Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 26. Rest of South America Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 27. Rest of South America Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 28. Rest of South America Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 29. Asia Pacific Oligonucleotide Synthesis, by Country USD Million (2017-2022)
  • Table 30. Asia Pacific Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 31. Asia Pacific Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 32. Asia Pacific Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 33. China Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 34. China Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 35. China Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 36. Japan Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 37. Japan Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 38. Japan Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 39. India Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 40. India Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 41. India Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 42. South Korea Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 43. South Korea Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 44. South Korea Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 45. Taiwan Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 46. Taiwan Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 47. Taiwan Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 48. Australia Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 49. Australia Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 50. Australia Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 53. Rest of Asia-Pacific Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 54. Europe Oligonucleotide Synthesis, by Country USD Million (2017-2022)
  • Table 55. Europe Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 56. Europe Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 57. Europe Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 58. Germany Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 59. Germany Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 60. Germany Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 61. France Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 62. France Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 63. France Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 64. Italy Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 65. Italy Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 66. Italy Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 67. United Kingdom Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 68. United Kingdom Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 69. United Kingdom Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 70. Netherlands Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 71. Netherlands Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 72. Netherlands Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 73. Rest of Europe Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 74. Rest of Europe Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 75. Rest of Europe Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 76. MEA Oligonucleotide Synthesis, by Country USD Million (2017-2022)
  • Table 77. MEA Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 78. MEA Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 79. MEA Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 80. Middle East Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 81. Middle East Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 82. Middle East Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 83. Africa Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 84. Africa Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 85. Africa Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 86. North America Oligonucleotide Synthesis, by Country USD Million (2017-2022)
  • Table 87. North America Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 88. North America Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 89. North America Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 90. United States Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 91. United States Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 92. United States Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 93. Canada Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 94. Canada Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 95. Canada Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 96. Mexico Oligonucleotide Synthesis, by Type USD Million (2017-2022)
  • Table 97. Mexico Oligonucleotide Synthesis, by Application USD Million (2017-2022)
  • Table 98. Mexico Oligonucleotide Synthesis, by End-User USD Million (2017-2022)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Oligonucleotide Synthesis: by Type(USD Million)
  • Table 111. Oligonucleotide Synthesis Oligonucleotide-Based Drugs , by Region USD Million (2023-2028)
  • Table 112. Oligonucleotide Synthesis Synthesized Oligonucleotides , by Region USD Million (2023-2028)
  • Table 113. Oligonucleotide Synthesis Reagents , by Region USD Million (2023-2028)
  • Table 114. Oligonucleotide Synthesis Others , by Region USD Million (2023-2028)
  • Table 115. Oligonucleotide Synthesis: by Application(USD Million)
  • Table 116. Oligonucleotide Synthesis Therapeutic , by Region USD Million (2023-2028)
  • Table 117. Oligonucleotide Synthesis Research , by Region USD Million (2023-2028)
  • Table 118. Oligonucleotide Synthesis Diagnostic , by Region USD Million (2023-2028)
  • Table 119. Oligonucleotide Synthesis: by End-User(USD Million)
  • Table 120. Oligonucleotide Synthesis Hospitals , by Region USD Million (2023-2028)
  • Table 121. Oligonucleotide Synthesis Pharmaceutical & Biotechnology , by Region USD Million (2023-2028)
  • Table 122. Oligonucleotide Synthesis Diagnostic Laboratories , by Region USD Million (2023-2028)
  • Table 123. Oligonucleotide Synthesis Academic Research Institutes , by Region USD Million (2023-2028)
  • Table 124. Oligonucleotide Synthesis Others , by Region USD Million (2023-2028)
  • Table 125. South America Oligonucleotide Synthesis, by Country USD Million (2023-2028)
  • Table 126. South America Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 127. South America Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 128. South America Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 129. Brazil Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 130. Brazil Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 131. Brazil Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 132. Argentina Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 133. Argentina Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 134. Argentina Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 135. Rest of South America Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 136. Rest of South America Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 137. Rest of South America Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 138. Asia Pacific Oligonucleotide Synthesis, by Country USD Million (2023-2028)
  • Table 139. Asia Pacific Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 140. Asia Pacific Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 141. Asia Pacific Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 142. China Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 143. China Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 144. China Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 145. Japan Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 146. Japan Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 147. Japan Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 148. India Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 149. India Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 150. India Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 151. South Korea Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 152. South Korea Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 153. South Korea Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 154. Taiwan Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 155. Taiwan Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 156. Taiwan Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 157. Australia Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 158. Australia Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 159. Australia Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 160. Rest of Asia-Pacific Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 161. Rest of Asia-Pacific Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 162. Rest of Asia-Pacific Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 163. Europe Oligonucleotide Synthesis, by Country USD Million (2023-2028)
  • Table 164. Europe Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 165. Europe Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 166. Europe Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 167. Germany Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 168. Germany Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 169. Germany Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 170. France Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 171. France Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 172. France Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 173. Italy Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 174. Italy Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 175. Italy Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 176. United Kingdom Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 177. United Kingdom Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 178. United Kingdom Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 179. Netherlands Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 180. Netherlands Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 181. Netherlands Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 182. Rest of Europe Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 183. Rest of Europe Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 184. Rest of Europe Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 185. MEA Oligonucleotide Synthesis, by Country USD Million (2023-2028)
  • Table 186. MEA Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 187. MEA Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 188. MEA Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 189. Middle East Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 190. Middle East Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 191. Middle East Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 192. Africa Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 193. Africa Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 194. Africa Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 195. North America Oligonucleotide Synthesis, by Country USD Million (2023-2028)
  • Table 196. North America Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 197. North America Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 198. North America Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 199. United States Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 200. United States Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 201. United States Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 202. Canada Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 203. Canada Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 204. Canada Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 205. Mexico Oligonucleotide Synthesis, by Type USD Million (2023-2028)
  • Table 206. Mexico Oligonucleotide Synthesis, by Application USD Million (2023-2028)
  • Table 207. Mexico Oligonucleotide Synthesis, by End-User USD Million (2023-2028)
  • Table 208. Research Programs/Design for This Report
  • Table 209. Key Data Information from Secondary Sources
  • Table 210. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Oligonucleotide Synthesis: by Type USD Million (2017-2022)
  • Figure 5. Global Oligonucleotide Synthesis: by Application USD Million (2017-2022)
  • Figure 6. Global Oligonucleotide Synthesis: by End-User USD Million (2017-2022)
  • Figure 7. South America Oligonucleotide Synthesis Share (%), by Country
  • Figure 8. Asia Pacific Oligonucleotide Synthesis Share (%), by Country
  • Figure 9. Europe Oligonucleotide Synthesis Share (%), by Country
  • Figure 10. MEA Oligonucleotide Synthesis Share (%), by Country
  • Figure 11. North America Oligonucleotide Synthesis Share (%), by Country
  • Figure 12. Global Oligonucleotide Synthesis share by Players 2022 (%)
  • Figure 13. Global Oligonucleotide Synthesis share by Players (Top 3) 2022(%)
  • Figure 14. Global Oligonucleotide Synthesis share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Alnylam Pharmaceuticals, Inc. Revenue, Net Income and Gross profit
  • Figure 17. Alnylam Pharmaceuticals, Inc. Revenue: by Geography 2022
  • Figure 18. Biogen Inc. Revenue, Net Income and Gross profit
  • Figure 19. Biogen Inc. Revenue: by Geography 2022
  • Figure 20. Danaher Corporation Revenue, Net Income and Gross profit
  • Figure 21. Danaher Corporation Revenue: by Geography 2022
  • Figure 22. Eurofins Scientific Revenue, Net Income and Gross profit
  • Figure 23. Eurofins Scientific Revenue: by Geography 2022
  • Figure 24. Ionis Pharmaceuticals, Inc. Revenue, Net Income and Gross profit
  • Figure 25. Ionis Pharmaceuticals, Inc. Revenue: by Geography 2022
  • Figure 26. Kaneka Corporation Revenue, Net Income and Gross profit
  • Figure 27. Kaneka Corporation Revenue: by Geography 2022
  • Figure 28. Diagenode Revenue, Net Income and Gross profit
  • Figure 29. Diagenode Revenue: by Geography 2022
  • Figure 30. LGC Limited Revenue, Net Income and Gross profit
  • Figure 31. LGC Limited Revenue: by Geography 2022
  • Figure 32. Merck KGAA Revenue, Net Income and Gross profit
  • Figure 33. Merck KGAA Revenue: by Geography 2022
  • Figure 34. Sarepta Therapeutics, Inc. Revenue, Net Income and Gross profit
  • Figure 35. Sarepta Therapeutics, Inc. Revenue: by Geography 2022
  • Figure 36. Thermo Fisher Scientific, Inc. Revenue, Net Income and Gross profit
  • Figure 37. Thermo Fisher Scientific, Inc. Revenue: by Geography 2022
  • Figure 38. Global Oligonucleotide Synthesis: by Type USD Million (2023-2028)
  • Figure 39. Global Oligonucleotide Synthesis: by Application USD Million (2023-2028)
  • Figure 40. Global Oligonucleotide Synthesis: by End-User USD Million (2023-2028)
  • Figure 41. South America Oligonucleotide Synthesis Share (%), by Country
  • Figure 42. Asia Pacific Oligonucleotide Synthesis Share (%), by Country
  • Figure 43. Europe Oligonucleotide Synthesis Share (%), by Country
  • Figure 44. MEA Oligonucleotide Synthesis Share (%), by Country
  • Figure 45. North America Oligonucleotide Synthesis Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Alnylam Pharmaceuticals, Inc.
  • Biogen Inc.
  • Danaher Corporation
  • Eurofins Scientific
  • Ionis Pharmaceuticals, Inc.
  • Kaneka Corporation
  • Diagenode
  • LGC Limited
  • Merck KGAA
  • Sarepta Therapeutics, Inc.
  • Thermo Fisher Scientific, Inc.
Select User Access Type

Key Highlights of Report


May 2023 234 Pages 79 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Oligonucleotide Synthesis Market are by type [Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Others], by end use application [Therapeutic, Research and Diagnostic].
The Oligonucleotide Synthesis Market is gaining popularity and expected to see strong valuation by 2028.
  • An increase in government funding for DNAstudies, synthetic biology initiatives, and rigorous research
  • R&D expenditure in pharmaceutical and biotechnology companies

Know More About Global Oligonucleotide Synthesis Report?